JoAnna K Leyenaar1, Tara Lagu, Meng-Shiou Shieh, Penelope S Pekow, Peter K Lindenauer. 1. From the *Division of Pediatric Hospital Medicine, Department of Pediatrics, Tufts University School of Medicine, Boston; †Center for Quality of Care Research; ‡Division of General Internal Medicine, Baystate Medical Center, Springfield; §Department of Medicine, Tufts University School of Medicine, Boston; and ¶Department of Public Health, School of Public Health and Health Sciences, University of Massachusetts, Amherst, MA.
Abstract
INTRODUCTION: Although pneumonia is a common reason for pediatric hospitalization among children with complex chronic conditions (CCC), treatment and outcomes have not been well-described. We characterized the presentation, management and outcomes of pneumonia in children with and without CCC and described how antibiotic management and outcomes vary among subgroups of children with CCC. METHODS: We conducted a cohort study of children <18 years with pneumonia across a large sample of US hospitals. Children were grouped according to CCC subgroups. Differences in disease management and outcomes were assessed using multivariable regression. RESULTS: Of the 31,684 children in our cohort, 11.9% had CCC. Children with CCC were more likely to receive intensive investigations and therapies, were less likely to receive aminopenicillins or third generation cephalosporins and were more likely to receive antibiotics against methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa and anaerobes. Compared with children without these conditions, children with CCC had significantly increased length of stay [relative risk 1.43, 95% confidence interval (CI) 1.39-1.48] and hospital costs (relative risk 1.38, 95% CI 1.33-1.43), with increased odds of antibiotic escalation (odds ratio 1.51, 95% CI 1.35-1.70), pneumonia complications (odds ratio 1.47, 95% CI 1.24-1.75) and readmission (odds ratio 4.0, 95% CI 3.2-5.0). DISCUSSION: Children with CCC comprise a significant proportion of children hospitalized for pneumonia and are at substantially increased risk of adverse outcomes. They have high rates of treatment with broad spectrum antibiotics, both at the time of hospitalization and subsequently. Research is needed to inform decision-making and guideline development, with goals of reducing adverse outcomes and unnecessary variation in management among children with CCC.
INTRODUCTION: Although pneumonia is a common reason for pediatric hospitalization among children with complex chronic conditions (CCC), treatment and outcomes have not been well-described. We characterized the presentation, management and outcomes of pneumonia in children with and without CCC and described how antibiotic management and outcomes vary among subgroups of children with CCC. METHODS: We conducted a cohort study of children <18 years with pneumonia across a large sample of US hospitals. Children were grouped according to CCC subgroups. Differences in disease management and outcomes were assessed using multivariable regression. RESULTS: Of the 31,684 children in our cohort, 11.9% had CCC. Children with CCC were more likely to receive intensive investigations and therapies, were less likely to receive aminopenicillins or third generation cephalosporins and were more likely to receive antibiotics against methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa and anaerobes. Compared with children without these conditions, children with CCC had significantly increased length of stay [relative risk 1.43, 95% confidence interval (CI) 1.39-1.48] and hospital costs (relative risk 1.38, 95% CI 1.33-1.43), with increased odds of antibiotic escalation (odds ratio 1.51, 95% CI 1.35-1.70), pneumonia complications (odds ratio 1.47, 95% CI 1.24-1.75) and readmission (odds ratio 4.0, 95% CI 3.2-5.0). DISCUSSION: Children with CCC comprise a significant proportion of children hospitalized for pneumonia and are at substantially increased risk of adverse outcomes. They have high rates of treatment with broad spectrum antibiotics, both at the time of hospitalization and subsequently. Research is needed to inform decision-making and guideline development, with goals of reducing adverse outcomes and unnecessary variation in management among children with CCC.
Authors: Tamar Lasky; Frank R Ernst; Jay Greenspan; Shirley Wang; Liliana Gonzalez Journal: Pharmacoepidemiol Drug Saf Date: 2010-11-11 Impact factor: 2.890
Authors: John S Bradley; Carrie L Byington; Samir S Shah; Brian Alverson; Edward R Carter; Christopher Harrison; Sheldon L Kaplan; Sharon E Mace; George H McCracken; Matthew R Moore; Shawn D St Peter; Jana A Stockwell; Jack T Swanson Journal: Clin Infect Dis Date: 2011-08-31 Impact factor: 9.079
Authors: Tamara D Simon; Jay Berry; Chris Feudtner; Bryan L Stone; Xiaoming Sheng; Susan L Bratton; J Michael Dean; Rajendu Srivastava Journal: Pediatrics Date: 2010-09-20 Impact factor: 7.124
Authors: Jay G Berry; David E Hall; Dennis Z Kuo; Eyal Cohen; Rishi Agrawal; Chris Feudtner; Matt Hall; Jacqueline Kueser; William Kaplan; John Neff Journal: JAMA Date: 2011-02-16 Impact factor: 56.272
Authors: Jay G Berry; Annapurna Poduri; Joshua L Bonkowsky; Jing Zhou; Dionne A Graham; Chelsea Welch; Heather Putney; Rajendu Srivastava Journal: PLoS Med Date: 2012-01-17 Impact factor: 11.069
Authors: Anna C Gay; Nicolas B Barreto; Sheree M Schrager; Christopher J Russell Journal: J Pediatr Gastroenterol Nutr Date: 2018-08 Impact factor: 2.839
Authors: Päivi H Salonen; Juha H Salonen; Hanna Säilä; Mika Helminen; Miika Linna; Markku J Kauppi Journal: Clin Rheumatol Date: 2019-11-16 Impact factor: 2.980
Authors: Joanna Thomson; Matt Hall; Jay G Berry; Bryan Stone; Lilliam Ambroggio; Rajendu Srivastava; Samir S Shah Journal: J Pediatr Date: 2016-08-22 Impact factor: 4.406